OncoSec Medical Inc (ONCSQ)

[chickpea598]

Sage Therapeutics is another example of a company gaining Breakthrough status with a small trial size.

Sage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression (enrollment estimate:32 patients)

SAGE-547 is also being developed as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE) in the global Phase 3 STATUS Trial.

Maybe Oncosec will gain a first line therapy designation for Melanoma if combo data is excellent.